The Epistemic Policies of Anti-Ageing Medicines in the European Union.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος:	The Epistemic Policies of Anti-Ageing Medicines in the European Union.
Συγγραφείς:	Marín Penella G; Department of Philosophy and Social Work, Faculty of Philosophy and Letters, University of the Balearic Islands, Carretera de Valldemossa Km. 7, 5, Palma de Mallorca, 07071, Spain. g.marin@uib.es.
Πηγή:	Health care analysis : HCA : journal of health philosophy and policy [Health Care Anal] 2026 Sep; Vol. 34 (3), pp. 356-371. Date of Electronic Publication: 2024 Nov 19.
Τύπος έκδοσης:	Journal Article
Γλώσσα:	English
Στοιχεία περιοδικού:	Publisher: Springer Netherlands Country of Publication: Netherlands NLM ID: 9432537 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-3394 (Electronic) Linking ISSN: 10653058 NLM ISO Abbreviation: Health Care Anal Subsets: MEDLINE
Imprint Name(s):	Publication: Dordrecht : Springer Netherlands Original Publication: Chichester, West Sussex, England : John Wiley & Sons, c1993-
Ιατρικοί όροι (MeSH):	Aging/drug effects , European Union , Health Policy*, Humans ; Policy Making
Περίληψη:	Anti-ageing medicines are products intended to extend lifespan and healthspan in humans that have a good potential use in public health policies. In the European Union, their development, production and consumption are dependent on regulatory science performed by the European Medicines Agency and its associated epistemic policies. They impose, among other things, an unfavourable burden of proof, a strict standard of proof and meta-methodological constrictions related to some theoretical issues. This results in a distribution of errors that tends to reduce false positives while increasing false negatives, leading to a set of social consequences that are generally accepted when the focus is placed on conventional medicines. However, when the same epistemic policies are applied to anti-ageing medicines, the distribution of errors is imbalanced, and undesirable outcomes like research discouragement and waiting time extensions appear. Three possible strategies that policymakers could implement to unblock the situation are presented for future reflection: the consideration of ageing as a disease, the application of methodological asymmetry and the use of biomarkers during clinical research. (© 2024. The Author(s).)
Competing Interests:	Declarations. Competing Interests: The author has no relevant financial or non-financial interests to disclose.
References:	BMJ Open. 2016 Jun 30;6(6):e011666. (PMID: 27363818) Cell Metab. 2020 Jul 7;32(1):15-30. (PMID: 32333835) Aging Cell. 2014 Jun;13(3):468-77. (PMID: 24341993) Trials. 2017 Aug 1;18(1):360. (PMID: 28764809) Aging Cell. 2015 Aug;14(4):497-510. (PMID: 25902704) Diabetes Obes Metab. 2014 Nov;16(11):1165-73. (PMID: 25041462) Exp Gerontol. 1988;23(4-5):223-39. (PMID: 3058488) Clin Pharmacol Ther. 2010 Dec;88(6):848-53. (PMID: 20962774) Elife. 2016 Aug 23;5:. (PMID: 27549339) J Eval Clin Pract. 2013 Jun;19(3):454-62. (PMID: 23692227) Trends Biotechnol. 2017 Nov;35(11):1062-1073. (PMID: 28778607) J Gerontol A Biol Sci Med Sci. 2014 Feb;69(2):119-30. (PMID: 23682161) Geroscience. 2018 Aug;40(4):361-364. (PMID: 30084059) Geroscience. 2021 Jun;43(3):1135-1158. (PMID: 33037985) Int J Technol Assess Health Care. 2020 Jun 25;:1-8. (PMID: 32638664) Diabetes Care. 2012 Apr;35(4):731-7. (PMID: 22442396) Cell. 2013 Jun 6;153(6):1194-217. (PMID: 23746838) Nat Commun. 2013;4:2192. (PMID: 23900241) Cell. 2023 Jan 19;186(2):243-278. (PMID: 36599349) BJOG. 2018 Dec;125(13):1716. (PMID: 29916205) Drugs Aging. 1998 Aug;13(2):93-7. (PMID: 9739498) Biomedicines. 2022 Oct 08;10(10):. (PMID: 36289777) Lancet Healthy Longev. 2021 Apr;2(4):e187-e188. (PMID: 36098117) J Med Philos. 2022 Dec 23;47(6):770-783. (PMID: 36562841) Philos Trans R Soc Lond B Biol Sci. 2011 Jan 12;366(1561):108-12. (PMID: 21115537) Clin Pharmacol Ther. 2022 Jan;111(1):21-23. (PMID: 34797920) Front Aging. 2022 Feb 04;3:820215. (PMID: 35821843) Cell Death Dis. 2014 Dec 04;5:e1552. (PMID: 25476900) Science. 2014 Oct 31;346(6209):587-91. (PMID: 25359967) Nat Prod Bioprospect. 2022 May 9;12(1):18. (PMID: 35534591)
Contributed Indexing:	Keywords: Anti-ageing medicines; Epistemic policies; European Medicines Agency; Policymaking; Regulatory science
Entry Date(s):	Date Created: 20241119 Date Completed: 20261016 Latest Revision: 20261019
Update Code:	20261019
PubMed Central ID:	PMC13675362
DOI:	10.1007/s10728-024-00497-9
PMID:	39560904
Βάση Δεδομένων:	MEDLINE

Περιγραφή
ISSN:	1573-3394
DOI:	10.1007/s10728-024-00497-9